We describe here a novel strategy to enhance the in vivo efficacy of replicating adenovirus therapy, using coinjection of plasmid DNA encoding a fusogenic viral glycoprotein. The combination of fusogenic membrane glycoprotein (FMG)-induced tumor cell fusion and infection with replicating adenovirus effectively treats even large established tumors at doses of plasmid DNA and virus that alone are ineffective. Adenoviral infection appears to increase the transduction of the tumor cells to a modest degree thereby boosting the FMG-mediated component of the therapy. Simultaneously, syncytial formation enhances the therapeutic effects of viral infection by increasing spread of adenoviral particles through the tumor cell population and by increasing titer of virus released from the tumor cells. This effect is due probably to release of intracellular viral particles upon tumor cell death and also to increased levels of E1A protein within syncytia, whose increased metabolic rate is associated with enhanced levels of protein expression. Cotransduction of tumor cells with replicating adenovirus and FMG-expressing vectors could either be combined within single replicating vectors or could be used in strategies using separate administration of two components, both at lower doses than required for either therapy alone.
Introduction
The problems associated with low titer and poor dispersal of recombinant viral vectors through established patient tumors have led to the advocacy of conditionally replication-competent viruses for the treatment of cancer. [1] [2] [3] [4] Several different families of essentially wild-type viruses have been described which appear to demonstrate tumor selective replication (see references in Kirn et al 1 and Vile 4 ). In addition, many groups have incorporated very specific molecular engineering into the adenoviral genome in order to confer tumor specificity of replication. The development of conditionally replication-competent adenoviral vectors 1, 2, 5 offers the chance to combine several different levels of both targeting and therapeutic approaches. Surface, 6 transcriptional, 7, 8 and cancer cell-specific genetic targeting 9, 10 have all been described with vectors derived from this virus. 1, 2, 5 In addition, the virus is lytic and a wide variety of therapeutic genes can be incorporated into adenoviral vectors. 2, 11 However, various important hurdles remain before replicating adenoviruses can be optimally efficacious, even in the context of local administration. 1, 12 Principal among these is increasing the spread of virus released within a tumor where other cell types, cell matrix, and areas of necrosis exist. 13, 14 Adenoviruses also remain largely cell associated such that the release of particles for tumor cell-tumor cell spread is limited relative to the total number produced. Moreover, the life cycle of the virus lasts a comparatively long time. In the developing race between the spread of virus (viral production and release) and tumor cell escape (by proliferation and escape from any controlling immune response), the balance in a growing tumor may be skewed in favor of tumor growth.
Various strategies have been described aimed at increasing the ability of the replicating adenovirus to win this race. These include engineering viral genes to enhance virus release and spread, 10, 15, 16 and arming the viruses with additional therapeutic genes that might either enhance viral cytotoxicity and/or provide additional therapeutic benefits separate to the properties of the virus itself. 11, 12 In this respect, we have previously demonstrated that gene transfer of viral fusogenic membrane glycoproteins (FMG) is a potent means to induce tumor cell killing through induction of fusion of tumor cells to form large multinucleated syncytia. [17] [18] [19] [20] [21] [22] In addition to being potent cytotoxic transgenes, [17] [18] [19] the formation and subsequent disintegration of syncytia is potently immunostimulatory. 21, 22 These properties suggest that intratumoral expression of FMG might provide both potent local tumor control and immunostimulatory vaccinating effects which should enhance their value for treatment of both remaining residual disease and distant metastases. 21, 22 We hypothesized that FMG expression within tumors might provide several potential therapeutic advantages when combined with infection with replicating adenoviruses. Potent cytotoxicity of the FMG could be combined with the lysis of infected cells by the virus to increase levels of tumor cell killing and the immune stimulatory mechanisms by which syncytia die and lead to vaccination against tumor might enhance the immune stimulatory value of replicating virotherapy. In support of this hypothesis, a recent report demonstrated that syncytia formed by expression of the HIV gp120 FMG facilitate the dispersal of adenoviral vectors through a culture of tumor cells and increase the efficiency of infection in vitro. 23 Moreover, inclusion of the Gibbon Ape Leukemia Virus (GALV) hyperfusogenic envelope FMG into an oncolytic herpesvirus significantly enhanced its antitumor efficacy in vivo. 24 Therefore, we tested whether interaction between the mechanism of action of FMG and the adenoviral life cycle may enhance the properties of replicating adenoviruses -particularly by increasing both the release of viral particles from infected cells that are killed by FMG and/or the spread of viral particles through the tumor via the syncytia and whether these two therapeutic approaches could be used in tandem to improve the efficacy of replicating adenovirotherapy.
Results
Cotransduction of human tumor cells with subtherapeutic doses of plasmid DNA expressing an FMG and replicating adenovirus leads to extensive tumor cell killing in vitro Transfection of 10 6 confluent tumor cells from different lines (Mel624 or Mel888, human melanoma; LnCap human prostatic carcinoma; U118 or U251 glioma) in vitro with 0.5 mg of plamsid DNA expressing the hyperfusogenic GALV FMG [17] [18] [19] (pCR3.1-GALV) routinely led to over 90% of the cells being killed 96 h following transfection. Similarly, infection of these cell lines with wild-type adenovirus serotype 5 (Ad5-Wt) at an m.o.i. of 0.1 led to cytopathicity of over 95% of cells (Figure 1a) . To study the interaction of FMG expression with Ad5-Wt infection, we selected treatment doses (0.01 mg plasmid DNA and 0.001 m.o.i. of Ad5-Wt) at which less than 10% of the tumor cell cultures were killed by either treatment alone (Figure 1b) . However, cotransduction with these suboptimal doses of both pCR3.1-GALV (0.01 mg) and Ad5-Wt (m.o.i. 0.001) induced significantly increased cytotoxicity compared to either treatment alone (495% cell killing) (Figure 1b) .
Syncytial formation enhances spread of adenoviral vector through a monolayer
The increased potency of GALV transfection in combination with infection by replicating virus might be explained simply by enhanced transfection efficiency of tumor cells in the presence of lysosomal disrupting adenoviral infection. To address this possibility, we measured GFP expression 48 h following transfection in cultures transfected with pCR3.1-GFP plasmid DNA (0.01 mg) in the presence or absence of coinfecting Ad5-Wt (m.o.i. 0.001). Although the results differed slightly for each cell line, the presence of Ad5-Wt (at these low m.o.i.) increased the transfection efficiency with plasmid DNA by, at most, about two-fold (typically increasing the number of GFP-positive cells from 4 to 6-7% in the case of Mel624 cells) (Figure 2a) . However, transfection with at least 50-fold more plasmid DNA was required to generate levels of cytotoxicity by GALV alone comparable to those seen in the combination of low-dose pCR3.1-GALV and Ad5-Wt (Figure 1a) , suggesting that enhanced transfection efficiency alone was not sufficient to explain the cooperation between GALV transfection and Ad5-Wt infection.
It has recently been reported that syncytial formation enhances the dispersion of adenoviral particles through a monolayer in vitro. 23 Therefore, we examined the ability of a replicating adenovirus to mobilize a replicationincompetent Ad-GFP vector from human tumor cells into murine B16 melanoma cells in coculture. Human tumor cells are highly susceptible to GALV-mediated cell fusion, but B16 murine melanoma cells do not express 
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A Ahmed et al the receptor for GALV and so will not fuse to GALVexpressing cells. 18 In the experiment described in Figure  2b 4 B16 cells, prelabeled with Cell Tracker Orange dye, were added to the cultures. Since B16 cells will not be incorporated into syncytia, the only way that the GFP reporter gene would transduce these cells would be through mobilization of Ad-GFP from the human tumor cells by the replication-competent Ad5-Wt. The number of GFP-transduced B16 cells at the end of the experiment (4 days later) was assessed by FACS for double-stained (orange and green) cells. Similar results were also seen with U118 and U251 cells.
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Syncytial cultures produce increased levels of viral titer
The increased mobilization of the Ad-GFP vector ( Figure  2b ) in the presence of syncytia may be due to an increase in the viral titer released on a per cell basis, an increase in the dispersal of the same amount of virus through the culture, 23 or both. The titer of cell-free virus released into the supernatants from the cultures of Figure 2b was significantly higher in the presence of syncytia relative to the same number of cells in nonfusing cultures (Po0.03 for U87 cells and Po0.01 for U118 cells) ( Table 1) . The difference in the amount of cell-associated virus (recovered from the cell pellets) was less marked between fusing and nonfusing cells but was still significantly enhanced from fusing cells (Po0.05 for U87 cells and Po0.01 for U118 cells) ( Table 1) . The increase in cell-free virus may in part be due to the increased lysis of the human tumor cells by FMG-mediated cell killing and release of cell-associated virus. These data show that presence of fusing cells increases both the total amount of virus produced and the amount of virus released into the culture supernatant, which at least partly will explain the more efficient spread of adenovirus through the culture (Figure 2b ). 23 Increased titer associated with syncytia occurs through post-transcriptional upregulation of E1A expression Reverse transcription-polymerase chain reaction (RT-PCR) analysis indicated that the increased viral titers described in Table 1 were not due to greater levels of transcription of the viral E1A gene within Ad5-Wtinfected, fusing human tumor cell cultures (Figure 3a) , data confirmed by Northern blotting (not shown). In contrast, levels of E1A protein were significantly enhanced (up to 10-fold depending upon the experiment) within fusing, as opposed to nonfusing, tumor cell cultures (Figure 3b ). These data are consistent with our previous observations, 20, 25 as well as those of others, 26, 27 that as syncytia develop they become highly metabolically active 20 and generate high levels of protein production compared to the same number of unfused cells.
Suboptimal doses of plasmid FMG DNA and replicating adenovirus cooperate to eradicate small established tumors
To investigate whether these in vitro results also have relevance to in vivo virotherapy, we first used direct intratumoral injection of suboptimal doses of Ad5-Wt or pCR3.1-GALV into very small established (0.2 cm diameter) human tumor xenografts. Three intratumoral injections of low doses of either pCR3.1-GALV (0.5 mg/ injection) or Ad5-Wt virus at a low dose (3 Â 10 7 PFU/ injection) had no significant effect on tumor cure ( Figure  4 ). However, simultaneous cotransduction of tumors with replicating adenovirus stocks and syncytia-inducing GALV plasmid DNA led to regression of all tumors under these conditions (Figure 4) such that, at the end of At the end of the experiment described in Figure 2 , cell culture supernatants were recovered and cells were trypsinized, washed in PBS, and lysed by three cycles of freeze thawing. Viral litters from the supernatants (cell free) and from the cell pellets (cell associated) were then determined by a plaque assay on 293 cells as described in Chong et al 
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A Ahmed et al the experiments shown in Figure 4a and b, 10 of 10 mice were tumor free in the (pGALV+Ad5-Wt) treatment groups. We confirmed that the therapeutic effects of pCR3.1-GALV and Ad5-Wt cotransduction were dependent upon expression of the GALV FMG by including an additional treatment group in the experiments of Figure 4 . Elsewhere, we have reported that gene expression can be effectively targeted to cells expressing an activated mutant RAS oncogene and/or high levels of P-MAPK The experiment of (a) was repeated except that the tumors were resected 2 days following injection with pGALV (GALV), replicating virus (Ad5-wt), or pGALV and Ad5-wt (GALV+Ad5-wt). Tumor cells were dissociated in vitro and analyzed by FACS for expression of the viral E1a protein using a rabbit polyclonal antibody against E1a (Santa Cruz Biotech, Santa Cruz, CA, USA) and an FITC-labeled anti-rabbit IgG. As controls for the FACS analysis, uninfected, cultured U251 cells were treated with no secondary antibody (untreated) or with both primary and secondary antibodies (negative). The positive control was U251 cells infected with wild-type Ad virus 24 h previously (positive).
by ligation of a therapeutic gene to the 3 0 untranslated region of the cyclooxygenase 2 gene (COX-3 0 UTR). 28 The COX-3 0 UTR efficiently destabilizes mRNA molecules in cells with low P-MAPK activity but selectively restabilizes the mRNA molecules and, therefore, protein expression in cells with high P-MAPK activity. 28 We constructed an expression plasmid, pCR3.1-GALV-COX (Figure 4c) , in which 469 bp of the COX-2 3 0 UTR destabilizes expression of the GALV FMG in low P-MAPK expressing cells (such as the U118 glioma) but selectively restabilizes expression in high P-MAPK expressing cells (such as U251). Cotransduction of small established U251 tumor xenografts with Ad5-Wt and pCR3.1-GALV-COX was as effective therapeutically as treatment with Ad5-Wt and pCR3.1-GALV (10 of 10 mice were tumor free at the end of the experiment in Figure  4a) ; however, treatment of the low P-MAPK tumor U118 with Ad5-Wt and pCR3.1-GALV-COX, in which GALV expression is significantly reduced by COX-2 3 0 UTRmediated destabilization of the mRNA, was no more effective than treatment with Ad5-Wt alone (Figure 4) . These results confirm that GALV expression can be targeted to tumor cells overexpressing P-MAPK and indicate that the therapeutic effects observed with cotransduction of tumors with Ad5-Wt and GALVexpressing plasmids are dependent upon expression of the FMG. To confirm the in vitro findings of enhanced viral spread through coexpression of the pGALV vector, the experiment of Figure 4a was repeated except that the tumors were resected 2 days following injection. Tumor cells were dissociated in vitro and analyzed by FACS for expression of the viral E1a protein. As can be seen from Figure 4d , even at early times after transduction in vivo, significantly enhanced numbers of infected cells were seen in tumors cotransduced with replicating virus and pGALV (B8% of the dissociated cells) compared to the virus alone (B1%).
Combination FMG gene therapy and adenovirotherapy leads to regressions of large established tumor xenografts
Finally, we showed that direct intratumoral administration of replicating adenovirus in combination with FMGmediated gene therapy is also significantly therapeutic in the context of large established tumors. Tumors allowed to develop to a mean diameter of 0.5-0.6 cm were injected a single time with low-dose Ad5-Wt (1 Â 10 7 PFU), pCR3.1-GALV (0.5 mg), or both. In tumors that are relatively fast growing, therapeutic effects of even the combined injection are too slow to manifest themselves before the experiments had to be terminated (tumor diameter 1.0 cm in any dimension). However, in slower growing tumor models such as LnCap (Figure 5 ), the cotransduction of tumors with Ad5-Wt with GALV generated a highly significant survival advantage (Po0.03) compared to treatment of large tumors with either treatment alone. As an added comparison and control, we also coinjected these tumors with Ad5-Wt and a plasmid expressing the HSVtk suicide gene (pCRS.1-HSVtk) (0.5 mg). Treatment of these animals with the prodrug ganciclovir generated some improvement in tumor regressions compared to the controls (Ad5-Wt, pCR3.1-HSVtk, or pCR3.1-GALV), although this did not turn out to be statistically significant ( Figure   5 ). Finally, we also injected tumors with pCR3.1-GFP or pCR3.1-GFP+Ad5-Wt and recovered tumors as they reached a diameter of 1.0 cm. Dissociation of these tumors followed by FACS analysis for GFP expression confirmed the earlier in vitro findings that the coadministration of Ad5-Wt with plasmid DNA increases the levels of transduction of tumor cells by the plasmid but only by a factor of 2-3 fold (data not shown).
Discussion
It is clear that several barriers still remain to the effective therapeutic use of replicating adenoviruses following direct intratumoral delivery. 1, 12 In particular, improvements will derive from virus designs that enhance virus release and spread through a tumor. Our in vitro studies here show that the FMG-mediated syncytial formation significantly enhances the efficacy of replicating adenoviral therapy through a combination of mechanisms. One of these is a moderate increase in the transfectability of cells with the GALV plasmid in the presence of coinfecting adenoviruses. This effect will boost the cytotoxicity associated with the FMG-mediated component of the therapy. [17] [18] [19] 27 However, quantitatively more significant, the levels of tumor cell expressed E1A protein were markedly increased in the presence of FMG-mediated cell-cell fusion. Elevated cellular levels of E1A were associated with significantly increased total viral titers (total virus produced from infected cells) as well as greater viral release from cultures of infected syncytial cultures compared to normal nonfusing monolayers. Finally, as a result of all of these effects, and consistent with a recent report using the HIV gp120 FMG, 23 syncytia also promoted enhanced spread of adenoviral particles through the tumor cell cultures.
The notable increase in the levels of E1A protein observed in syncytial cultures compared to nonfusing 6 LnCap tumor cells in matrigel were injected subcutaneously in athymic nude mice and allowed to develop until they were large established tumors (0.5-0.6 cm diameter). Groups of mice (10 mice per group) were injected a single time with low-dose Ad5-Wt (1 Â 10 7 PFU), pCR3.1-GALV (0.5 mg), or both (Ad5-Wt+pGALV). Additional groups were injected with pCR3.1-GFP (0.5 mg)+Ad5-Wt (1 Â 10 7 PFU) (Ad5-Wt+pGFP) or with pCR3.1-HSVtk (0.5 mg) alone (pHSVtk) or in combination with Ad5-Wt (1 Â 10 7 PFU) (Ad5-Wt+pHSVtk). Animals injected with pHSVtk or Ad5-Wt+pHSVtk were treated with the prodrug ganciclovir i.p. at 80 mg/kg for 5 days. Tumor growth was monitored for a further month. Animals were killed when tumor size reached 1.0 cm in any diameter.
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A Ahmed et al cultures was not explicable by increased transcription of the E1 gene. We have previously reported that syncytia die through nonapoptotic mechanisms 22 that are associated with metabolic depletion due to a very high metabolic activity of syncytia. 20 Moreover, expression of several different transgenes is significantly increased from syncytial cultures. 25, 26 Therefore, the increased metabolic activity induced by syncytial formation appears to convert syncytia into transient protein production factories associated with increased levels of translation of pre-existing mRNAs which, in this case, lead to increased levels of E1A and viral production. These effects may reflect a mechanism by which syncytial-inducing viruses ensure maximal levels of viral protein and particle production before the death of the parasitized cell.
In addition to the overall increase in viral titer, syncytial formation is also associated with increased release of adenoviral particles on a per cell basis. Most probably, this is due in part at least to lysis of infected cells thereby releasing intracellular particles that would otherwise remain cell associated for longer. Therefore, the increased level of viral production coupled with accelerated release of viral particles and the resultant dispersal through tumor cell cultures would suggest that combination therapy with FMG expression and replicating adenovirus infection may overcome some of the problems associated with the use of replicating adenovirotherapy which have been seen to date.
To confirm this hypothesis in vivo, we demonstrated that the efficacy of intratumoral injection of replicating adenovirus is greatly enhanced by the coinjection of an FMG-encoding plasmid. This combinatorial approach was sufficient to eradicate very small, established tumors at viral doses where injection of the virus, or plasmid alone, was not effective. Intratumoral injection into large, established, slow-growing tumors was also significantly more effective than either low-dose plasmid GALV or Ad5-Wt therapy alone. These therapeutic effects were not due to increased destruction of the stroma between tumor cells which might act in patient tumors to impede virus spread because the stroma in these experiments are of murine origin which do not express fusion competent receptors for the GALV FMG. These data suggest that replicating adenoviruses expressing the GALV FMG will be significantly more potent than viruses lacking the transgene. Indeed, several reports have shown that therapeutic transgenes can be efficiently and appropriately expressed within the context of replicating adenoviruses, and the expression of an FMG cDNA from a viral locus expressed late in the infection cycle might be optimal in this respect. [29] [30] [31] There may also be confounding effects that the viral genome exerts when considering the FMG strategy as part of a replicating virus. For example, the E3-encoded receptor internalization and degradation (RID) complex has been shown to remove certain receptors from the surface of cells and it may exert similar effects on the levels of the surface-expressed FMG. However, there are also potential risks in enhancing the potency of replicating adenoviruses by the insertion of an FMG into the vector genome. These considerations emphasize the importance of including the FMG component as part of additional strategies that have already been developed to ensure the selectivity of replication to tumor cells. Therefore, there is also potential value in keeping the FMG component of the therapy separate from the replicating virus. Cotransduction of virus and plasmid as described here allows for the use of significantly lower doses of both components (FMG plasmid and virus). In addition, should systemic release of virus or plasmid occur, the chances of them being carried together significant distances to normal tissues are low, thereby reducing the overall chances of toxicity associated with either type of treatment. In addition, we have shown that targeting of GALV expression to tumor cells is possible at both transcriptional 32 and post-transcriptional levels as demonstrated in this work and in Ahmed et al. 28 These strategies could be combined with pre-existing conditionally replicating adenoviruses which have tumor targeting already built in either at the level of transcriptional regulation using selective promoters driving essential replicative 7, 33, 34 or therapeutic genes 11, 35, 36 or at the genetic level using viral mutants with tumor cell selective replicating properties. [1] [2] [3] One further advantage that induction of FMGmediated syncytial formation may have in the presence of replicating adenoviral infection stems from the observation that syncytial cell death is associated with release of tumor antigens via a strong immunostimulatory mechanism, 22 associated with efficient cross-priming of host antigen-presenting cells 21, 22 and potent in vivo vaccination against tumor-derived epitopes. 21 The experiments described here in nude mice cannot address these issues, but our previous observations suggest that combining FMG killing with adenoviral therapy should also significantly enhance the immunotherapeutic benefits of treatments with conditionally replicating adenoviruses. 21, 22 In summary, we have described a novel strategy to enhance the in vivo efficacy of replicating adenovirus therapy, using coinjection of plasmid DNA encoding a fusogenic viral glycoprotein. This approach can be developed through generation of conditionally replicating adenoviruses incorporating the FMG cDNA or as separate combination gene/virotherapy components. The presence of the FMG provides potent cytotoxicity and potential immunostimulation against tumor-derived antigens as well as secondary attributes (enhanced viral expression, production, and dispersion), which will complement the replicative and cytotoxic properties of the replicating adenovirus.
Materials and methods

Cell lines
The human tumor cell lines, U118, U87, U251 gliomas, and LnCap prostate were obtained from the American Type Culture Collection (ATCC; Manassas, VA, USA) and were maintained as a monolayer in Dulbecco's modified Eagle's medium (DMEM, Life Technologies, Inc.) containing 10% fetal bovine serum. Mel624 and Mel888 human melanoma cell lines have been described elsewhere. 18 
Plasmid construction and transfection
The pCR3.1-GALV expression plasmid consists of the human CMV promoter driving expression of the hyperfusogenic GALV envelope cDNA as described in The 469 bp human COX-2 3 0 UTR cDNA clone was isolated by RT-PCR amplification using human COX-2 sequence-specific primers. Cells were transiently transfected using Effectene transfection reagent (QIAGEN, Valencia, CA, USA) according to the manufacturer's instructions.
Wild-type replication-competent adenovirus
Wild-type adenovirus serotype 5 was purchased from Qbiogene, CA, USA. The virus was grown on 293 cells and purified on cesium chloride gradient columns for use in in vitro and in vivo experiments.
Immunoblot analysis for detection of proteins
Protein extracts were prepared by lysis of infected cells with radioimmunoprecipitation assay buffer (10 mM Tris buffer (pH 7.4), 425 mM NaCl, 1% NP-40, 1% deoxycholate, 0.1% SDS, 100 ml of protease inhibitor cocktail (Roche, Indianapolis, IN, USA), 5 mM EGTA, 100 mM Na 3 VO 4 , 50 mM Na pyrophosphate, 50 mM NaF), and protein expression was determined by Western blot after separation of 10 mg of cell lysate on 10% SDS-PAGE and transferred to a PVDF membrane (Millipore, Bedford, MA, USA). The protein concentration was determined using a BCA protein assay with bovine serum albumin as a standard (Pierce, Rockford, IL, USA). The detection of adenovirus E1A proteins was accomplished using rabbit polyclonal antibody (Santa Cruz Biotech., Santa Cruz, CA, USA) against the target protein. Immunoreactive bands were visualized by enhanced chemiluminescence (Pierce, Rockford, IL, USA).
RT-PCR analysis
Total cellular mRNA was extracted by using an Rneasy kit (QIAGEN, Valencia, CA, USA), according to the manufacturer's protocol. RNA concentrations were measured and 1 mg total cellular RNA was reverse transcribed in a 20 ml volume using oligo-(dT) as a primer and Moloney murine leukemia virus reverse transcriptase (Pharmacia LKB Biotechnology, Milton Keynes, UK). A cDNA equivalent of 1 ng RNA was amplified by the PCR using primers specific for the viral E1A gene. PCR was performed in a 50 ml reaction mixture with 250 mM of each dNTP, 100 nM of primers, 5 ml of 10 Â buffer (HT Biotechnology Ltd, Cambridge, UK), and 1 U of super-Taq DNA polymerase (HT Biotechnology Ltd, Cambridge, UK) using 30 cycles (941C, 1 min denaturation; 581C, 1.5 min annealing; and 721C, 2 min extension). The reaction mix (25 ml samples) was analyzed by agarose gel electrophoresis (1%) in TAE buffer containing 0.2 mg/ml ethidium bromide. In all experiments, a mock PCR (without added DNA) was performed to exclude contamination. To exclude carry over of genomic DNA during the RNA preparation step, controls were also carried out in which the reverse transcriptase enzyme was omitted.
In vivo studies
To establish subcutaneous tumors, 4-to 5-week-old athymic nu/nu female mice (Harlan Sprague Dawley, Inc., Indianapolis, IN, USA) were injected with 2 Â 10 6 tumor cells (U118, U251) or 5 Â 10 6 tumor cells in matrigel (LnCap). When the tumors measured the appropriate size (palpable (0.2cm)) or 0.5-0.6 cm, plasmid DNA, wild-type Ad-5, or a combination was injected intratumorally in 50 or 100 ml volume. In order to administer the combination treatment intratumorally, the pGALV and Ad5-Wt components were mixed in a syringe and injected simultaneously. Animals were examined every other day and euthanized if tumor size reached 1.0 Â 1.0 cm.
